MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Novocure.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Novocure.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Novocure.com most likely does not offer any adult content.
Popular pages
-
About Us - Novocure
Novocure strives to extend survival in aggressive forms of cancer by developing and commercializing its innovative Tumor Treating Fields therapy.
-
Our Pipeline - Novocure
Tumor Treating Fields have shown a consistent anti-mitotic effect in our preclinical and clinical research. The science of TTFields has the potential to extend beyond glioblastoma and mesothelioma.
-
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary ...
-
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Full year 2021 net revenues of $535 million, an increase of 8% year-over-year Invested record $201 million in 2021 in research and development initiatives intended to advance Tumor Treating Fields sci...
-
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of
Pre-specified interim analysis concluded that the INNOVATE-3 study should proceed to final analysis as planned ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the results of...
-
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating
Final data from INNOVATE-3 trial anticipated in 2023 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 t...